

S P A R K: Translating Academic Discovery to Patients' Benefit; Lessons from our 14 Years of S P A R K at Stanford and Around the World

Daria Mochly-Rosen

Dept of Chemical and Systems Biology

Stanford University, School of Medicine



9th International Symposium on Higher Order Structure of Protein Therapeutics

- What is **SPARK**, why do it and what are its goals
- A brief guide to the entrepreneur from an ex-entrepreneur
- Why **SPARK Global** and why now



The challenge – how to translate good ideas to great solutions?

- The value gap: academic projects are considered premature: not robust
 - The chosen indication and/or solution are inappropriate, or not realistic
 - The findings are not reproducible
- 2. A knowledge gap: Academic inventors have no knowledge in drug development
- **3. A cultural gap:** academic inventors do not value applied science and industry views academic as unreliable
 - Translational research is not aligned with academic reward



Our goals – overcoming the three gaps


SPARK aims to *increase* the impact of academic inventions for the benefit of patients worldwide, through:

- <u>Increase the value</u> by adding industry standard studies, focusing on fast solutions for patients *regardless* of economic outcome.
- <u>Increase knowhow</u> by a unique education and mentoring of the innovative academic scientists *within* academia;
- <u>Increasing mutual respect</u> between industry and academic scientists



The participants

5





S PARK A T S T A N F O R D


The formula to success

- Many volunteer advisors with many academicians
- In one room, ongoing
- On university campus
- No hierarchy
- Not aiming to reach a consensus
- Learning from successes AND failures

Mix scientists from industry and academia to work on solutions



SPARK works



117 graduated projects

To start-ups: 43 projects

To existing companies: 13 projects

Non-commercial (In clinical trial): 17 projects

Failed POC /other – 44 projects



Our Record

- Return of Investment: For every \$1 received by a SPARK project, the PI received \$8 in grant funding for Stanford.
- Publications: Three SPARK project-related publications per project.
- Commercial Funding: Start-ups based on SPARK's licensed technologies raised an average of \$16 million per project.
- Attrition: SPARK start-ups have less than 10% attrition rate; only 4 of the 43 start-ups folded.




Some of the startups and their pharma partners



Hereditary transthyretin amyloidosis, a case for a *Higher Order Structure of Protein Therapeutics*

- A rare genetic condition affects an estimated 50,000 people worldwide.
- >120 mutations associated with hATTR amyloidosis.
- In hATTR amyloidosis, mutations in the TTR gene causes misfolding



Eidos Therapeutics soars after IPO tops targets, raises \$106M




eidos a bridgebio company

Isabella Graef, PhD Asst. Professor of Pathology

hATTR – hereditary form of amyloidosis caused by mutation in transthyretin protein, resulting in cardiomyopathy and neuropathy

AG10 - Rationally designed small molecule to that stabilizes mutant transthyretin protein, preventing amyloid deposition in heart and nerve tissues





Why is the attrition rate so low?

Attrition: SPARK start-ups have less than 10% attrition rate; only 4 of the 43 start-ups folded.

- Inventors are better partners with investors- educated in pharma work
- Projects selected for and mentored by MANY industry experts
- Connections with many companies, investors & future workforce



What do we teach?

- Start with the **end product** in mind
- Funding based on **milestones**
- Teach project management skills



- Provide product development-focused education
- Mentorship by industry veterans
- Provide introductions to collaborators, companies, contractors and investors
- Teach entrepreneurship skills



• What is **SPARK** and what are its goals

- A brief guide to the entrepreneur from an ex-entrepreneur
- Why SPARK Global and why SPARK Global now



Dallas Sept 4, 2004







Parsabiv approved:

Parsabiv[®] - launched in the U.S. in the first quarter of 2018.



Approved in the US and Europe





Worldwide sales for second quarter reporting by Amgen (\$102 M)

KAI-4169 Licensed to Ono for Japan before company was acquired by Amgen

Approved in Japan, too

Product photograph



ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp

Entrepreneurship in a nutshell:

Lesson 1: Consult! Consult! Consult!



Entrepreneurship in a nutshell:

Lesson 1: Consult! Consult! Consult!

Lesson 2: Dare! Don't fear to fail – because you will!

Lesson 3: Persevere! Have no ego!



Lesson 5: Keep basic research active

Lesson 6: Think before giving up

Lesson 7: Good data are not enough – Know your market

Lesson 8: Your company is only as good as your team!



• What is **SPARK** and what are its goals

- A brief guide to the entrepreneur from an ex-entrepreneur
- Why **SPARK Global** and why **SPARK Global** now



Why build a **SPARK** program?

- To translate the amazing science of academia to products that benefit patients – our social responsibility
- Because it provides important education to students and postdocs for job that they are likely to hold
- Because it may trigger biotech industry and contribute economically to the area.



How to begin

- 1. Internal champions
- 2. Program director(s) with relevant experience
- 3. Volunteer industry advisors (many)
- 4. Core facilities (HTS, proteomics, formulation, etc)
- 5. Funding
- 6. Flexibility



SPARKing in the world




SPARKGLOBAL TRANSLATIONAL SCIENTISTS WITHOUT BORDERS

Our values

Non-for-profit Ethical Based on volunteering spirit For patients and society

Why **SPARK** global?

So that together, we can better address global health threats.







- What is **SPARK**, why do it and what are its goals
- A brief guide to the entrepreneur from an ex-entrepreneur
- Why **SPARK Global** and why now



SPARKing to benefit patients and society

SPRINGER BRIEFS IN PHARMACEUTICAL SCIENCE & DRUG DEVELOPMENT

Daria Mochly-Rosen Kevin Grimes Editors

A Practical

Academia

Guide to Drug

Development in

The SPARK Approach

Springer

Daria Mochly-Rosen, mochly@stanford.edu

26

SPARKing to benefit patients and society